Novagali Pharma Receives US FDA Orphan Drug Designation for Vekacia(R) for the Treatment of Vernal Keratoconjunctivitis.

PR Newswire Europe, May, 2007

EVRY, France, May 25 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company, announced today orphan drug designation granted by the U.S. Food and Drug Administration (FDA) to Cyclosporine A drug Vekacia(R), a patented cationic emulsion, for the treatment of Vernal Keratoconjunctivitis (VKC).

VKC is a rare and severe form of chronic allergic conjunctivitis affecting mostly children and young adults. It is characterized by painful ocular discomfort, itching and intense photophobia, which severely debilitates patients and virtually forces them to live in the dark with the obvious consequences on school attendance and learning.

In March 2006, the Committee for Orphan Medical Products (COMP), a division of the European Medicines...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement